Who is sponsoring NCT00758199?

NCT00758199 is sponsored by Bp Consulting, Inc.

What drugs are being tested in NCT00758199?

Interventions: Bromfenac, Moxifloxacin hydrochloride, Prednisolone Acetate.

What is the status of NCT00758199?

NCT00758199 is currently COMPLETED.

Last reviewed 2012-03-14 · How we verify

Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery

NCT00758199 Phase 4 COMPLETED

The objective of this study is to determine if an extension of bromfenac BID monotherapy is effective in the decreasing retinal thickening post cataract IOL placement surgery. No studies exist on how long to treat with an NSAID post cataract IOL placement surgery. Currently, NSAID therapy post IOL placement surgery is in conjunction with steroid treatment, lasting approximately 3 weeks. This study is designed to examine if there is benefit to extending NSAID monotherapy in regards to macular thickening and the incidence of CME.

Details

Lead sponsor	Bp Consulting, Inc
Phase	Phase 4
Status	COMPLETED
Enrolment	49
Start date	2008-07
Completion	2010-01

Conditions

Cataracts

Interventions

Bromfenac
Moxifloxacin hydrochloride
Prednisolone Acetate

Primary outcomes

OCT with macular thickening — 3-6 weeks

Countries

United States